Summary
Background Persistent asymptomatic Plasmodium falciparum infections are common in malaria-endemic settings, but their contribution to transmission is poorly understood.
Methods A cohort of children and adults from Tororo, Uganda was closely followed for 24 months by continuous passive surveillance and routine assessments. P. falciparum parasite density, gametocyte density and genetic composition were determined molecularly; mosquito membrane feeding assays were performed on samples from participants with symptomatic and asymptomatic infections.
Findings From October 2017 to October 2019, we followed all 531 residents from 80 households. Parasite prevalence was 5·8% by microscopy and 17·3% by PCR at enrolment and declined thereafter. We conducted 538 mosquito feeding experiments on samples from 107 individuals. Mosquito infection rates were strongly associated with gametocyte densities of participants. Considering both transmissibility of infections and their relative frequency, the estimated human infectious reservoir was primarily asymptomatic microscopy-detected infections (83·8%), followed by asymptomatic submicroscopic (15·6%) and symptomatic (0·6%) infections. Over half of the infectious reservoir was children aged 5-15 years (56·8%); individuals <5 years (27·5%) and >16 years (15·7%) contributed less. Four children were responsible for 62·6% (279/446) of infected mosquitos and were infectious at multiple timepoints.
Interpretation Individuals with asymptomatic infections were important drivers of malaria transmission. School-aged children were responsible for over half of all mosquito infections, with a small minority of asymptomatic children highly infectious. Demographically targeted interventions, aimed at school-aged children, could further reduce transmission in areas under effective vector control.
Funding National institute of Health, Bill & Melinda Gates Foundation, European Research Council.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by the National Institutes of Health as part of the International Centers of Excellence in Malaria Research (EICEMR) program (AI089674) and another program (AI075045), the Bill & Melinda Gates Foundation (INDIE OPP1173572) and a fellowship from the European Research Council to TB (ERC-2014-StG 639776). TB is further supported by a fellowship from the from The Netherlands Organisation for Scientific Research (Vidi fellowship NWO project number 016.158.306). MDC is supported by the Fogarty International Center (P0529898 and TW009343) and the Centennial Travel Award from the American Society of Tropical Medicine and Hygiene. JIN is supported by Fogarty International Center (TW010365). BG is a Chan Zuckerberg Biohub investigator. The ClinEpiDB platform is supported by the Bill & Melinda Gates Foundation (OPP1169785).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was received from the Uganda National Council of Science and Technology (HS119ES), Makerere University School of Medicine, the University of California, San Francisco and the London School of Hygiene & Tropical Medicine
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Cohort data are available through a novel open-access clinical epidemiology database resource, ClinEpiDB. Data for the study conducted from October 2017 through October 2019 (referred to as PRISM2) can be found at https://clinepidb.org/ce/app/record/dataset/DS_51b40fe2e2
